Business Wire

HITHIUM

20.5.2024 12:12:14 CEST | Business Wire | Press release

Share
Hithium and Maxxen cooperate in exclusive strategic partnership in Türkiye

Stationary battery manufacturer Hithium and Maxxen, a 100 percent subsidiary of Kontek Energy, which has 30 years of energy industry experience have announced their exclusive strategic partnership at the Türkiye launch of this cooperation on May 17, 2024, in Istanbul, Türkiye.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240520113866/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

Hithium - exclusive strategic partnership with Maxxen in Türkiye (Photo: Business Wire)

Hithium and Maxxen have joined forces in an exclusive strategic partnership agreement in the field of energy storage for the battery energy storage system and the trademark rights of Hithium. This will result in the creation of more sustainable energy systems globally and locally.

As Hithium GM of the Middle East region and Head of Global Delivery Centre, Sean Sun commented: “It's very promising to cooperate with Maxxen to contribute to energy transition with both parties in Türkiye. This bonding relationship will enhance our market competitiveness and together dedicate to the needs of affordable, reliable and flexible energy storage solution.”

As Maxxen & Kontek CEO, Tolga Murat Özdemir commented: “We, at Maxxen, believe that cooperating with Hithium as one of the leading manufacturer of BESS Systems in the world focused only in Stationary Energy Storage, will help create a synergy to expand the business of two companies around the region not only by being closer to the projects to supply shorter deliveries and better after sale services with outstanding quality and manufacturing processes but at the same time using the capabilities of Maxxen in contributive digital solutions will also help develop value added derivative complete solutions to the related markets.”

This partnership between Hithium and Maxxen represents an important step towards a cleaner future. The objective is to play a key role in making a difference in the energy storage sector by establishing a battery energy storage systems production facility in Türkiye. In furtherance of the aforementioned agreement, the two companies have agreed that they will endeavor to develop groundbreaking innovations in the field of sustainable energy. Hithium and Maxxen are committed to contributing to the worldwide energy transition by accelerating the spread of battery energy storage technologies to wider audiences.

About Hithium

Founded in 2019, Hithium is a leading manufacturer of top-quality stationary energy storage products for utility-scale as well as commercial and industrial applications. With four distinct R&D centers and multiple “intelligent” production facilities, Hithium’s innovations include groundbreaking safety improvements to its lithium-ion batteries as well as increases in lifecycle. With decades of cumulative experience in the field among its founders and senior executives, Hithium leverages its specialization in BESS to deliver partners and customers unique advances in energy storage. The company is headquartered in Xiamen, China, with locations in Shenzhen, Chongqing, Munich, Dubai, New York and California. Hithium has shipped 20+ GWh of BESS products to date.

About Maxxen

Maxxen, 100% subsidiary of Kontek Enerji, aims to provide solutions to use energy more sustainably and efficiently in the field of battery energy storage technologies.

Maxxen's goal is to shape the future of the energy sector by storing the excess energy produced in order to balance the stabilization problems that may arise as the share of intermittent renewable energy sources in total electricity production increases, providing this stored energy to the grid when needed and using renewable energy efficiently. In this context, it is aimed to produce energy storage containers from LFP (Lithium Iron Phosphate) cells, the most widely used technology of energy storage systems, referred to as ESS.

Maxxen will offer innovation and added value to the sector with battery energy storage technologies with the quality assurance of Kontek Energy.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240520113866/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Rigaku and Tohoku University Establish a New Research Institute for X-Ray Metrology28.8.2026 16:00:00 CEST | Press release

Rigaku Corporation, a group company of Rigaku Holdings and a global solutions partner for X-ray analytical systems (Head Office: Akishima, Tokyo; President and CEO: Jun Kawakami; “Rigaku”), and Tohoku University (Sendai, Miyagi; President: Teiji Tominaga; “Tohoku University”) have established the Rigaku-Tohoku University Co-Creation Research Institute for X-ray Metrology: Beyond The Limits (the “Institute”) at Tohoku University on August 1, 2026. The Institute will advance X-ray metrology technology, develop new metrology methods, and foster the next generation of researchers through an initial three-year collaboration, with the possibility of extension based on its achievements. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260828688510/en/ Inside the Institute As semiconductors become smaller, more multilayered, and incorporate a wider range of materials, manufacturing processes are becoming increasingly complex. X-ray me

BLK: Portfolio Company of Enry’s Island S.p.A., Lists on Euronext Dublin28.8.2026 15:34:00 CEST | Press release

Enry’s Island S.p.A. (WBAG:EIOS), an international venture builder with headquarters in the Tremiti Islands and the Metaverse, announces that BLK Global PLC, one of the portfolio companies within its ecosystem, has successfully completed its admission to trading on Euronext Access Dublin. Trading in the company’s shares commenced on Friday, July 31, 2026, under ticker BLKX and ISIN GB00BPSKS130. BLK was one of the thousands of applications received by Enry’s Island which, following an assessment process based on the Enry’s Model, was selected for a one-year incubation and acceleration programme. The programme supported the company through its subsequent growth stages, ultimately leading to its current stock market listing. Alessandro Pacciana, Investor Relations Manager of Enry’s Island S.p.A., said: “BLK’s listing is the second stock market listing in two years among Enry’s Island’s portfolio companies, while Enry’s Island itself is the world’s first listed venture builder. We are pro

Zambon Announces European Commission Approval of Hopledo® for Adults with Parkinson's Disease and Moderate to Severe Motor Fluctuations28.8.2026 11:00:00 CEST | Press release

Hopledo® is a first-in-class, oral, modified-release formulation of levodopa/carbidopa (LD/CD) approved for the treatment of motor fluctuations of Parkinson’s disease Zambon expects to begin the phased introduction of Hopledo® across European markets starting October 2026 The approval is based on data from the Phase 3 RISE-PD trial where Hopledo® demonstrated a significant increase in Good ON time compared with immediate-release LD/CD with fewer daily doses and a comparable safety profile Zambon today announced that the European Commission (EC) has granted marketing authorization for Hopledo® (modified-release levodopa/carbidopa) for the treatment of adult patients with Parkinson’s disease and moderate to severe motor fluctuations who have not been sufficiently stabilized with oral levodopa/dopa decarboxylase (DDC) inhibitor-based treatment regimens. Zambon expects to begin the phased introduction of Hopledo® across European markets starting October 2026. The company is working closely

MTG-I2 Safely in Orbit, Unlocking Faster and Sharper Weather Monitoring Across Europe28.8.2026 10:16:00 CEST | Press release

The Meteosat Third Generation Imager 2 satellite (MTG-I2) has successfully passed its first critical post-launch milestones, completing the first full Meteosat Third Generation constellation in orbit. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260828243790/en/ Credit: Arianespace livestream The imager satellite MTG-I2 is safely in orbit and operating as expected following its successful launch yesterday at 22:11 CEST on board an Ariane 6 rocket from Europe’s Spaceport in French Guiana. Our teams have established communication with the spacecraft, which has also deployed its solar panels to ensure its autonomous production of energy. MTG-I2 is in perfect shape to start its Launch and Early Operations Phase that will bring it to a higher orbit, 36 000km above Earth over the following two weeks, where a longer period of calibration and validation of its instruments will begin. This summer’s extreme weather and wildfires hav

New Daiichi Sankyo Data Underscore the Effect of Bempedoic Acid in the Real-World Management of Dyslipidemia and Cardiovascular risk28.8.2026 10:00:00 CEST | Press release

Analyses from the multinational MILOS study show that LDL-C reductions achieved with up to one year of treatment with bempedoic acid-containing therapies translate to a 17.1% relative reduction and a 4.8% absolute reduction in predicted 10-year cardiovascular risk.1 Real-world data demonstrated clinically relevant mean LDL-C reductions of at least 24.9%, regardless of patient gender or glycaemic status, after one year of follow-up.2,3 Findings presented at ESC Congress 2026 reinforce the clinical value of bempedoic acid in routine clinical practice, and demonstrate the continued investment of Daiichi Sankyo in addressing outstanding unmet needs in cardiovascular disease (CVD). Daiichi Sankyo (TSE:4568) today announced new results from the MILOS study that demonstrate the real-world impact of bempedoic acid administered either alone or as a fixed-dose combination with ezetimibe, in the management of dyslipidaemia. Presented at the European Society of Cardiology Congress 2026 in Munich,

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye